Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) had its price objective hoisted by Stifel Nicolaus from $105.00 to $109.00 in a report released on Thursday morning. The brokerage currently has a buy rating on the pharmaceutical company’s stock.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

VRTX has been the subject of several other research reports. Leerink Swann reissued an outperform rating and set a $113.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, August 15th. JMP Securities reissued a buy rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 16th. Maxim Group reissued a hold rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 16th. RBC Capital Markets reissued a buy rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 16th. Finally, Robert W. Baird reissued an outperform rating and set a $128.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, August 16th. Eleven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $118.45.

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 91.26 on Thursday. The firm’s 50 day moving average is $97.70 and its 200 day moving average is $89.49. The company’s market cap is $22.61 billion. Vertex Pharmaceuticals has a 12-month low of $75.90 and a 12-month high of $134.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The business earned $431.61 million during the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The business’s quarterly revenue was up 159.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.54) earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals will post $1.00 EPS for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 1,100 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $100.79, for a total transaction of $110,869.00. Following the transaction, the director now directly owns 268,225 shares of the company’s stock, valued at $27,034,397.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $84.82, for a total transaction of $435,126.60. Following the transaction, the director now directly owns 273,355 shares in the company, valued at $23,185,971.10. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of VRTX. Mycio Wealth Partners LLC increased its position in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares during the period. Conning Inc. increased its position in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock worth $494,000 after buying an additional 20 shares during the period. Northwestern Mutual Investment Management Company LLC increased its position in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,435 shares of the pharmaceutical company’s stock worth $812,000 after buying an additional 28 shares during the period. Cleararc Capital Inc. increased its position in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Cleararc Capital Inc. now owns 6,028 shares of the pharmaceutical company’s stock worth $479,000 after buying an additional 33 shares during the period. Finally, Checchi Capital Advisers LLC increased its position in shares of Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock worth $152,000 after buying an additional 73 shares during the period. 96.26% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.